IBS008738|cas:385425-03-6|西域试剂

IBS008738,98.22%

产品编号：Bellancom-112821| CAS NO：385425-03-6| 分子式：C₂₂H₂₂N₄O₂| 分子量：374.44

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-112821	￥2600.00	杭州北京（现货）
Bellancom-112821	￥4000.00	杭州北京（现货）
Bellancom-112821	￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

IBS008738

产品介绍

IBS008738 是一种有效的 TAZ 激活剂。IBS008738 稳定C2C12 细胞中的 TAZ，增加未磷酸化的 TAZ 水平，增强 MyoD 与肌细胞生成素启动子的结合，上调 MyoD 依赖性基因转录，并与肌肉生长抑制素竞争。IBS008738 增强 C2C12 细胞的肌生成并促进肌肉损伤模型中的肌肉修复。

生物活性

IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model.

体外研究

IBS008738 (0, 24, 48, 72 h) enhances TAZ expression, with a peak at 24 h.
IBS008738 (10 μM; 0, 24, 72 h) enhances mRNAs of myogenic markers but not of myofusion markers.
IBS008738 (10 μM; 24h) enhances mRNAs of IL-10 in C2C12 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	C2C12 cells
Concentration:
Incubation Time:	Treated for 0, 24, 48, 72 h under differentiation conditions after 24 h under growth conditions.
Result:	Enhanced TAZ expression, with a peak at 24 h.

RT-PCR

Cell Line:	C2C12 cells
Concentration:	10 μM
Incubation Time:	0, 24, 72 h under differentiation
Result:	Enhanced mRNAs of myogenic markers but not of myofusion markers.

体内研究
(In Vivo)

IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles.
IBS008738 (30 μM, 100 μL) prevents Dexamethasone-induced muscle atrophy.
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female BALB/cByJ mice
Dosage:	3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS)
Administration:	Injected into the tibialis anterior (TA) muscle of mice under anesthesia.
Result:	Facilitated muscle repair in Cardiotoxin-injected muscles.

Animal Model:	Six-week-old female BALB/cByJ mice
Dosage:	30 μM (100 μL)
Administration:	Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13.
Result:	Prevented Dexamethasone-induced muscle atrophy.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female BALB/cByJ mice
Dosage:	3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS)
Administration:	Injected into the tibialis anterior (TA) muscle of mice under anesthesia.
Result:	Facilitated muscle repair in Cardiotoxin-injected muscles.

Animal Model:	Six-week-old female BALB/cByJ mice
Dosage:	30 μM (100 μL)
Administration:	Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13.
Result:	Prevented Dexamethasone-induced muscle atrophy.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female BALB/cByJ mice
Dosage:	3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS)
Administration:	Injected into the tibialis anterior (TA) muscle of mice under anesthesia.
Result:	Facilitated muscle repair in Cardiotoxin-injected muscles.

Animal Model:	Six-week-old female BALB/cByJ mice
Dosage:	30 μM (100 μL)
Administration:	Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13.
Result:	Prevented Dexamethasone-induced muscle atrophy.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (133.53 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6707 mL	13.3533 mL	26.7065 mL
5 mM	0.5341 mL	2.6707 mL	5.3413 mL
10 mM	0.2671 mL	1.3353 mL	2.6707 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.25 mg/mL (3.34 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (3.34 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (3.34 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (3.34 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明